Astek Diagnostics Achieves Key Milestone with Successful Completion of Q4-50 Alpha Feasibility Study
Baltimore, MD – December 19, 2024
Astek Diagnostics is pleased to announce the successful completion of its Q4-50 Alpha Feasibility Study, a major step forward in the development of its groundbreaking Jiddu™ Platform. Conducted in partnership with MedStar National Rehabilitation Hospital (NRH), the study tested 50 urine samples from neurogenic bladder syndrome patients with suspected urinary tract infections. The results validate the potential of Astek Diagnostics’ innovative diagnostic technology.
Following the completion of the Jiddu™ Alpha prototype over the summer, the device underwent rigorous bench testing milestones prior to sample testing. In November 2024, patient sample testing officially began as part of the Q4-50 milestone. The goal was to compare the Alpha prototype’s performance to the current standard of urine culturing for urinalysis and antibiotic susceptibility testing (C&S).
The Alpha prototype achieved remarkable accuracy in its results:
Accuracy: 87.10%
Specificity: 93.33%
Sensitivity: 86.67%
These outcomes demonstrate the prototype's ability to deliver results comparable to the gold-standard C&S testing in one hour, underscoring its potential to revolutionize diagnostics.
"The successful completion of the Q4-50 milestone is a significant step for Astek Diagnostics," said Dr. Al-Adhami, CEO of Astek Diagnostics. "These promising results validate our efforts to deliver faster and more accurate diagnostics and pave the way for the next phase of our product development."
“We are encouraged by the promising results from the Jiddu Alpha prototype,” said Suzanne Groah, MD, MSP, Chief Medical Officer at Astek Diagnostics. “As we expand our studies in 2025, we look forward to comparing Jiddu’s performance against standard urine culture methods. Additionally, we will evaluate how Jiddu’s antibiotic susceptibility testing supports clinicians in making more informed decisions regarding UTI diagnosis and antibiotic selection in clinical settings.”
With the successful completion of Q4-50, Astek Diagnostics will pivot to developing the market-ready Jiddu™ Beta prototype in early 2025. Clinical trials for the Beta prototype are scheduled for Q2 2025, with a full market launch targeted for Q1 2026. In parallel, testing of the Alpha prototype will continue at MedStar NRH to further validate the platform’s performance in real-world clinical settings.
About Astek Diagnostics
Astek is a precision diagnostics company developing the Jiddu™ Platform to confirm bacterial infections and assess antibiotic sensitivity across multiple sample types: urine, CSF, would effluent, and blood. Astek has prioritized going to market in 2025 with a urine-based test which identifies urinary tract infections and antibiotic sensitivity in one hour. The company is part of the Y Combinator (S21) and has received support from Harvard University, NSF, FDA, BARDA, NIH and numerous VC funds and angel investors.
For more information, visit www.astekdx.com.
Media Contact:
Mustafa Al-Adhami, PhD
Founder & CEO
Astek Diagnostics, Inc.
mustafa@astekdx.com
www.astekdx.com
